Evidence map›Paper›PMID 41836238›Full record

ArticleFrontiers in oncology2026

Development of a second primary tumor during maintenance immunotherapy in metastatic gingival squamous cell carcinoma: a case report.

Xiaoyu Liu, Hanquan Sun, Shangzhong Chen, Shasha He, Min Ouyang, Ping Liu

Abstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiaoyu Liu *Department of Oncology, Loudi Central Hospital, Loudi, Hunan, China.
Hanquan Sun *Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Shangzhong ChenDepartment of Oncology, Loudi Central Hospital, Loudi, Hunan, China.
Shasha He *Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Min OuyangDepartment of Geriatrics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Ping LiuDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple primary tumors are defined as two or more distinct malignancies occurring simultaneously or metachronously in the same patient. This report describes a patient with extensively metastatic gingival squamous cell carcinoma who achieved radiologic complete remission (CR) through combined immunotherapy, chemotherapy, and local radiotherapy. The patient continued immunotherapy maintenance for 38 months. Two years after CR, a second primary tumor emerged. The second tumor was surgically resected, followed by postoperative maintenance therapy with oral Tegafur-Gimeracil-Oteracil (S-1) capsules. As of the last follow-up on January 14, 2025, nearly two years after the second surgery, the patient showed no local recurrence or distant metastasis. This case suggests that while immunotherapy provided excellent overall tumor control, it failed to prevent the occurrence of the second primary tumor. Whether prolonged immunotherapy (38 months vs. the standard 24 months) positively impacts patient prognosis requires further exploration. This case highlights that even after achieving CR with immunotherapy, vigilance for the development of second primary tumors during maintenance therapy is crucial.

Indexed as

case reportgingival squamous cell carcinoma (GSCC)head and neck squamous cell carcinoma (HNSCC)immunotherapysecond primary tumors (SPTs)

Identifiers

PMID41836238
PMCPMC12982103

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.